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Abstract
Objectives: 1. To assess the long-term effectiveness of a comprehensive cardiac
rehabilitation programme on quality of life and survival in patients with a large spectrum of
cardiovascular diseases (myocardial infarction, acute coronary syndrome, percutaneous
transluminal coronary angioplasty and coronary artery bypass grafting). 2. To establish the
degree of correlation between expected improvement of health-related quality of life and
improvement in physical function attributable to rehabilitation in the intervention group, in
comparison with similar changes in the conventional care group.
Design: Randomized, controlled, parallel-group design (intervention/conventional care).
Setting: Akershus County, southeast of Oslo City, Norway.
Participants: 500 patients, men and women, aged 40–85 years, who have sustained at
least one of the above-mentioned cardiovascular diseases.
Interventions: 8 weeks of supervised, structured physical training of three periods of 20 min
per week, targeting a heart rate of 60–70% of the individual’s maximum; home-based
physical exercise training with the same basic schedule as in the supervised period;
quantification of patients’ compliance with the exercise programme by the use of
wristwatches, information stored in the watch memory being retrieved once a month during
the 3-year follow-up period; and life-style modification with an emphasis on the cessation of
smoking and on healthy nutrition and weight control.
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angioplasty; QLMI = quality of life after MI.
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Introduction
Post-infarct rehabilitation, a process of restoring physical
and psychological fitness, has become increasingly
employed in hospitals both in the USA and Europe during
the past three decades, primarily as a vehicle of secondary
prevention with the ultimate goal of reducing long-term
mortality. However, rehabilitation programmes from the
1960s were particularly focused on psychologically based
therapy and exercise training, with a gradual shift during
the 1990s to programmes of comprehensive rehabilitation
in the context of randomized, controlled trials [1–4].
The clinical benefits of cardiac rehabilitation are clear, as
demonstrated by several reports and meta-analyses [5–8].
The benefits included decreased mortality, improved
quality of life, and possibly lower costs because of lower
rates of rehospitalization.
Important components of rehabilitative programming for
coronary patients include progressive physical activity, edu-
cation of patient and family, and psychosocial and voca-
tional counselling. Conventionally, rehabilitation is
incorporated into traditional care during hospitalization for
myocardial infarction (MI), coronary bypass surgery or
angioplasty; it involves the patient’s family and social envi-
ronment as a support system, and continues in the office of
the patient’s physician and/or in a variety of community facil-
ities. Initiation and coordination of rehabilitative efforts fall
within the responsibility of both hospital doctors (usually
cardiologists) and the primary care physician. The multifac-
torial nature of morbidity after acute myocardial infarction
(AMI) indicates the need for and relevance of a multifactorial
approach and the contribution of a multidisciplinary team.
In spite of improvements in the quality of previous cardiac
rehabilitation trials and the encouraging conclusions of
meta-analysis that indicate a reduction of about 20% in
total and cardiovascular mortality, there are still controver-
sies on the overall effectiveness of rehabilitation generally
[9–11]. Several factors have contributed to this situation,
which in practice translates into a poor external validity for
many of the trials reported in the past 20 years.
Many uncontrolled observations making unjustifiable
claims probably reflect nothing more than the natural reso-
lution of morbidity after MI. Small trials, as many trials are
in the field of cardiac rehabilitation, are prone to bias
towards exaggeration, with the consequent risk of false
positive findings.
Among the drawbacks encountered in most of the trials is
the use of highly selected patients or volunteers in specialist
centres and very restrictive inclusion criteria (eg the exclu-
sion of patients with associated co-morbidities) [12]. Most
trials included only patients aged less than 65 years, yet
more than 40% of MI patients are more than 65 years old
[13–15]. Patients older than 70 years account for one-third
to one-half of patients with AMI admitted to hospital. The
application of trial results to clinical practice is hampered by
the fact that such patients, although accounting for up to
half of the cases of MI and having a disproportionately high
mortality, are significantly under-represented in clinical trials.
Most trials have included only men (eg the WHO trial [7]),
yet about 30% of MI patients are women [16,17].
The overall heterogeneity of the rehabilitation trials per-
formed so far, mainly generated by the employment of
exclusive designs, impairs their external validity. General-
ization of the conclusions beyond the groups studied is
therefore not possible. This, in turn, makes the effective-
ness of rehabilitation in all potentially eligible patients
questionable, because it is largely untested.
Study design
The CORE Study is designed as a pragmatic (effective-
ness) trial meant to evaluate an intervention with already
proven efficacy [secondary prevention of coronary heart
disease (CHD)], but with special emphasis on the assess-
ment of quality of life (five different domains) and on the
quantification of patients’ long-term compliance with
regular physical exercise. The intervention is offered to a
heterogeneous group of people under ordinary clinical cir-
cumstances, covering a wide age range, for both sexes
and with heterogeneous characteristics (co-morbidities).
Through the specific nature of the primary and secondary
objectives, the trial is a combination of qualitative and
quantitative research, targeting both soft and hard mea-
sures of outcome.
To ensure a rigorous methodological approach, considerable
effort has been dedicated to developing appropriate strate-
gies for screening, recruitment and assessment [18,19].
The CORE study will be a randomized, controlled, single
centre trial, driven by the Medical Department of the Aker-
shus Central Hospital in Oslo, Norway.
Subjects are being recruited from a population of about
300,000 inhabitants of Akershus County during a 12-
month period starting in April 2000. Men and women
between 40 and 85 years old with at least one of the
inclusion criteria [AMI, stabilized acute coronary syndrome
(ACS), percutaneous transluminal coronary angioplasty
(PTCA) or coronary artery bypass grafting (CABG)] will be
screened for participation in the study.
The follow-up period will continue until the last randomized
patient has been followed up for 36 months. Patients not
randomized because of scheduled coronary angiography,
scheduled PTCA or CABG or who necessitated one ofc
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these alternatives after being randomized will be
approached and checked or rechecked for eligibility within
6 weeks of the invasive investigation, or alternatively after
a PTCA or CABG.
Co-morbidities such as hypertension, heart failure and dia-
betes will not be exclusion criteria in themselves; however,
a certain degree of severity of these conditions, as stipu-
lated in the exclusion criteria, might exclude a particular
patient from being randomized.
Study objectives
The primary objective is to assess patients’ quality of life in
the light of their health-related experiences after having
sustained an AMI/ACS or PTCA/CABG and to establish
the extent of correlation of quality of life with improvement
in physical function attributable to rehabilitation.
The secondary objectives are to study total and cardiovas-
cular mortality, morbidity and recurrence rates of coronary
events throughout a 3-year follow-up period, and to deter-
mine the efficacy and feasibility of a comprehensive rehabil-
itation programme encompassing home-based long-term
follow-up with the aim of preserving continuity of care.
Eligibility criteria
Inclusion criteria
1. Males and females aged 40–85 years.
2. Unequivocal hospital-verified, definite AMI less than
3 months ago defined by either unequivocal ECG evi-
dence of a new MI with or without typical history, or a
typical rise and fall in biochemical markers of myocar-
dial damage, where the maximal value reached is
greater than twice the upper limit of the hospital refer-
ence range, with either a typical history and/or new
ECG changes indicating myocardial ischaemia.
3. Patients with a recent ACS (that is, established CHD
with a stabilized condition after a recent unstable
episode) defined by either a changed pattern of
angina or chest pain at rest or on minimal exertion or
emotion (two 5-min episodes or one episode lasting
more than 10 min) in addition to evidence of underly-
ing coronary artery disease (at least one of the follow-
ing): ECG (ST segment depression, T wave inversion
or transient ST elevation); enzyme elevation [tropo-
nine I or T, creatine kinase (CK) or CK-MB]; evidence
of coronary artery disease on angiography or perfu-
sion scanning.
4. PTCA patients (more than 4 weeks after a PTCA).
5. CABG patients (more than 4 weeks after a CABG).
6. Ambulatory patients who have signed a declaration of
consent.
Exclusion criteria
1. Unstable angina pectoris.
2. Scheduled angiography.
3. Clinically significant heart failure (peripheral oedema,
rales over two-thirds of the chest, pulmonary conges-
tion on chest X-ray, cardiothoracic ratio more than
0.5, ejection fraction less than 35%).
4. Severe hypertension (systolic blood pressure more
than 200 mmHg and/or diastolic blood pressure
more than 105 mmHg) despite treatment to decrease
blood pressure.
5. Symptoms of orthostatic hypotension or a supine sys-
tolic blood pressure of 90 mmHg or lower.
6. Severe arrhythmias persisting after the acute phase
of the AMI (frequent premature ventricular beats,
grade III–IV of the Lown classification, atrial flutter,
partial or complete atrioventricular block).
7. Psychoneurotic disorders (depression or/and anxiety).
8. Severe obstructive airway disease with permanent
respiratory insufficiency [interfering with performance
in the exercise tolerance test (ETT)].
9. Uncontrolled diabetic mellitus (HbA1C more than 9).
10. Severe orthopaedic disability (interfering with ETT
performance).
11. Serum creatinine more than double the local upper
normal limit (in the context of known renal disease).
12. Alanine amino-transferase or aspartate amino-trans-
ferase more than three times the local upper limit (in
the context of known liver disease).
13. Presence of any condition that limits life expectancy
(eg cancer or haematological diseases).
14. Problems expected with compliance or follow-up.
15. Participation in another trial or study during the past
30 days.
16. Stroke with severe physical disability (interfering with
ETT performance).
Ethics and informed consent
The final protocol was approved by an independent Insti-
tutional Review Board affiliated to the University of Oslo.
Written consent is obtained from patients after the study
objectives, design, scope of the intervention, and risks and
benefits have been explained carefully. Risks are
described as related to the ETT with a cycle ergometer
and partly to the physical training itself. Exercise testing
has documented safety when appropriate guidelines are
followed [20], and risks of injury and/or sudden cardiac
death during physical training can be minimized with
medical evaluation, risk stratification, supervision and edu-
cation [21]. Emergency equipment and trained personnel
will be available to deal with unusual situations that might
arise [22–24].
Sample size and statistical analysis
Prospective international registries (OASIS registry [25]
and PRAIS UK registry [26]) indicate rates of death or MI
of about 10–12% at 6 months. On the basis of further lit-
erature reviews, an overall mean proportion of survival ratefor all subjects enrolled in the study after 3 years of follow-
up would be about 80%.
A desired 10% improvement in the survival of patients in
the intervention group, with 80% power and 0.05% signifi-
cance level, will require 250 subjects per group and 500
subjects in total [27].
An ‘intention to treat’ analysis is to be strictly applied, sub-
jects withdrawn will be followed up for endpoints and
attention will be paid to appropriate handling of missing
information (sensitivity analysis).
Pearson’s correlation coefficient will be calculated for the
QLMI (quality of life after MI) scores between groups and
for QLMI scores and patients’ improvement in physical
activity as quantified through the ETT.
The responsiveness of the questionnaire will be evaluated
by calculating the ratio between the change in subjects’
score between the baseline and the 12-month, 24-month
and 36-month visits and the pooled standard deviation of
change during this period.
The c2 test and independent-samples t test respectively
will be used for comparing proportions and means of tar-
geted parameters, with 0.05 as the level of statistical sig-
nificance and a 95% confidence interval around point
estimates.
Subgroup analysis will be performed for the three age
groups: 40–65 years, 66–75 years and 76–85 years.
Randomization
After having ascertained the patient’s eligibility and will-
ingness to participate in the study and after written
consent has been given, randomization takes place with
allocation to the intervention (I) or the conventional care
(CC) group [28–30]. The particular allocation and its
consequences for the long-term follow-up are clearly
explained to each patient.
Separate randomization sheets are generated by a com-
puter program for the two main groups (I and CC) and for
three age subgroups. The pseudorandom number genera-
tor is a linear congruent algorithm of Park and Miller with
Bays–Durham shuffling. It has a period of over 2 × 109 [31].
The process of randomization will be concealed.
Risk stratification, follow-up and investigation
schedule
During hospitalization, risk stratification is performed in all
patients with the aim of selecting the high-risk individuals
at this early stage and deciding on the need for invasive
investigation, eventually leading to PTCA or CABG.
Before discharge from the hospital, patients assigned to
both the I and CC groups will be exposed to a standard-
ized programme developed for addressing the knowledge
and skills of cardiac assessment, drug use and adherence
as well as for facilitating behaviour change in relation to
lifestyle and modification of risk factors.
After discharge, an outpatient ETT is scheduled to be per-
formed on every patient within 6 weeks, with the aim of
assessing their baseline physical capacity.
Follow-up visits after the first ETT are scheduled for both
groups (I and CC) at 6-month intervals for an average
period of 3 years (Fig. 1). However, a prolonged period for
follow-up visits may be decided upon, on the basis of
several objective factors emerging with time (accrual rate,
losses to follow-up, overall patient compliance, or rate of
major endpoint). Parameters checked at different visits are
indicated in the investigation schedule (Table 1).
Intervention programme
Patients in the I group will be targeted for a structured
secondary prevention programme under the supervision of
a team of workers who will use the knowledge, skills, tech-
niques and services of a variety of medical consultants,
healthcare personnel and community resources to imple-
ment rehabilitation in a wide spectrum of patients with
CHD (AMI, ACS, PTCA and CABG) and to establish con-
tinuity in the provision of care. The ultimate goal is an
improvement in the quality of life and survival in all these
patients, regardless of age or associated co-morbidities.
A patient education curriculum has been designed as a
standardized programme developed for the modification of
secondary risk factor through structured counselling of the
particular patient and his or her closest family member.
The following topics will be focused on: nutrition, smoking
and alcohol habits, behaviour modification, social and
familial support and compliance with the drug regimen
[32–51]. Special teaching classes on these topics will be
given repeatedly during the 8 weeks after the first ETT, in
parallel with a physical training programme given during
the same period.
Brief counselling will be offered individually at the 6-month
visits.
Special consideration has been given to targeting a pro-
gramme of systematic physical training tailored to each
individual, on the basis of the results of an initial ETT per-
formed 6 weeks after an acute event. The programme con-
sists of 8 weeks of supervised outpatient physical training.
At the end of this programme a new ETT will quantify any
improvement in the patient’s physical condition (total work
capacity at the end of the trial [W], absolute oxygen con-
sumption [VO2], relative energy expenditure in metabolic
Current Controlled Trials in Cardiovascular Medicine    Vol 1 No 3 The CORE Investigatorsequivalents [1 MET = 3.5 kcal/min] and the rate–pressure
product). A structured physical training programme will be
tailored for each individual in the form of a home-based
exercise programme. Compliance with the programme
and the results attained will be quantified by the use of a
wristwatch given to every patient in the intervention group
[52–56]. In the interval between two visits, the patients in
the I group will be asked to come to the outpatient clinic
every fourth week (five times between two 6-month visits).
During these short visits lasting 10–15 min, the informa-
tion stored in the wristwatch will be printed out and docu-
mented on the case report form.
http://cvm.controlled-trials.com/content/1/3/177
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Figure 1
Study design.
Table 1
Investigation schedule
Investigation V0 V1 V6 V12 V18 V24 V30 V36 V42* V48*
History ×
Clinical examination × × × × × ×
QLMI questionnaire A B B B† BB † BB † BB †
Blood pressure × ××××××××
ECG × × × × × ×
Laboratory tests × × × × × ×
Smoking + S-cotinine ××××××××××
Exercise level ××××××××
Nutrition + BMI × ××××××××
Alcohol status ××××××××××
ETT ×‡×× ×
Medication ××××××××××
Adverse events ××××××××××
*If applicable. †Patient’s evaluation questionnaire. ‡ETT at the start and the end of 8 weeks of supervised exercise training. V0–V48, visits at 6-month
intervals; BMI, basal metabolic index.A final ETT will be performed on subjects allocated to both
groups (I and CC) at the end of the trial and compared
with the results of the baseline ETT. (A detailed descrip-
tion of the ETT protocol, the 8-week supervised pro-
gramme and the home-based exercise training programme
will be reported elsewhere.)
Assessment of quality of life
Measurement of the quality of life has evolved as the end-
point of choice and the ultimate goal of rehabilitation pro-
grammes after MI [57–59]. Although survival, return to
previous employment or comfortable retirement are para-
mount issues for patients having sustained one of the four
pathological entities focused on, there are other concerns
dealing with the quality of life such as the persistence of
symptoms, the ability to perform appropriate activities at
different stages of the illness and the ability to care for
oneself. Such issues reflect the quality of life in terms of
personal satisfaction and a sense of well-being.
The disease-specific QLMI questionnaire developed by N
Oldridge and G Guyatt [60] has been tested in the
context of a randomized rehabilitation trial and has been
shown to have a high degree of reliability in measuring
changes in health-related quality of life over time while
being more responsive than other questionnaires
employed so far. We decided on the use of a modified
version of the QLMI questionnaire with new items cover-
ing the patient’s period before admission to hospital, and
10 items omitted from the original version.
The following domains are covered in the questionnaire:
pre-hospital period (three questions), symptom domain
(five questions), restriction domain (two questions), confi-
dence domain (three questions), self-esteem domain (three
questions) and emotion domain (three questions). There
are seven graded answers to each question (one to seven
points per question), leading to a final score assessed at
randomization and after 1, 2 and 3 years of follow-up.
Conclusions
The CORE Study is a randomized, controlled, parallel-
group, single-centre trial to investigate the benefits of a
systematically implemented comprehensive rehabilitation
programme, with its main focus on quality of life and sur-
vival in patients with large spectrum of CHDs. Important
features include:
1. targeting patients with AMI, stabilized ACS, PTCA
and CABG;
2. planning the enrolment of a large number of women;
3. broad age range (40–85 years);
4. concealed randomization;
5. recruitment of sufficient patients to provide adequate
statistical power to detect effects of small size;
6. provision of an individually tailored yet standardized,
well-defined programme for both physical exercise
and change of risk factors for CHD;
7. monitoring of patient safety and data integrity by an
independent data and safety monitoring board;
8. ascertainment of primary and secondary endpoint
and planned intention-to-treat analysis completely
and in an unbiased manner.
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